Accelovance Continues Expansion with Opening of Research Triangle Park, North Carolina Office
Accelovance announced the opening of a new office in Research Triangle Park, North Carolina.
Accelovance, a therapeutically focused clinical research organization (CRO), announced today the opening of a new office in Research Triangle Park (RTP), North Carolina. This office opening supports continued corporate expansion and provides Accelovance's clients and employees with a presence in the research-active landscape of the RTP area of North Carolina. The new offices are close to many current and potential clients and offer a rich base of technical talent to support continued corporate growth.
"Building and scaling a high-quality team is a key driver to our continued success as a business," said Stephen Trevisan, President and CEO. "RTP was one of our top choices as a location, since it offers an excellent talent pool of research professionals who have the experience to help us better serve our customers."
Accelovance plans to add up to 15 new clinical operations positions in the RTP area this year.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
